Research progress on radical concurrent chemoradiotherapy for locally advanced esophageal cancer
Wang Shijia, Xiao Zefen
Department of Radiation Oncology, National Cancer Center / National Clinical Research Center for Cancer / Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Abstract:The current standard treatment modality for unresectable locally advanced esophageal cancer is radical concurrent chemoradiotherapy. In this article, research progress on radiotherapy techniques, differences in radiotherapy dose and target volume, exploration in concurrent chemotherapy and immunotherapy was reviewed, aiming to provide reference and evidence for clinical treatment.
Wang Shijia,Xiao Zefen. Research progress on radical concurrent chemoradiotherapy for locally advanced esophageal cancer[J]. Chinese Journal of Radiation Oncology, 2022, 31(11): 1065-1069.
[1] Zhang SW, Sun KX, Zheng RS, et al.Cancer incidence and mortality in China, 2015[J]. JNCC, 2020,1(1): 2-11. DOI:10.1016/j.jncc.2020.12.001. [2] Shah MA, Kennedy EB, Catenacci DV, et al.Treatment of locally advanced esophageal carcinoma: ASCO guideline[J]. J Clin Oncol, 2020,38(23):2677-2694. DOI: 10.1200/JCO.20.00866. [3] NCCN. NCCN Clinical Practice Guidelines in Oncology: Esophageal and Esophagogastric Junction Cancers Version 4.2020[S/OL].[2021-04-15] http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. [4] 谭立君, 肖泽芬, 张红星, 等. 不能手术食管癌三维放疗与同期放化疗生存比较[J].中华放射肿瘤学杂志,2015,24(2):106-110. DOI: 10.3760/cma.j.issn.1004-4221. 2015. 02.002. Tan LJ, Xiao ZF, Zhang HX, et al.Survival comparison of three-dimensional radiotherapy alone with concurrent chemoradiotherapy for non-surgical esophageal carcinoma[J].Chin J Radiat Oncol,2015,24(2):106-110. DOI: 10.3760/cma.j.issn.1004-4221.2015.02.002. [5] 张安度, 韩晶, 韩春,等. 1257例食管鳞癌三维放疗+化疗的临床研究[J]. 中华放射肿瘤学杂志, 2017,26(5):517-521. DOI:10.3760/cma.j.issn.1004-4221.2017.05.008. Zhang AD, Han J, Han C, et al.Clinical effect of three-dimensional radiotherapy combined with chemotherapy for esophageal squamous cell carcinoma: a study of 1257 patients[J]. Chin J Radiat Oncol,2017,26(5):517-521. DOI:10.3760/cma.j.issn.1004-4221.2017.05.008. [6] 王鑫, 王澜, 陈俊强, 等. 多中心食管鳞癌根治性三维放疗的预后分析——3JECROG R-01[J].中华放射肿瘤学杂志,2018,27(11):959-964. DOI:10.3760/cma.j.issn.1004-4221. 2018.11.002. Wang X, Wang L, Chen JQ, et al.Prognostic analysis of definitive three-dimensional radiotherapy for non-surgically resectable esophageal squamous cell carcinoma: a multi-center retrospective study (3JECROG R-01)[J]. Chin J Radiat Oncol,2018,27(11):959-964. DOI:10.3760/cma.j.issn.1004-4221. 2018.11.002. [7] Lin SH, Wang L, Myles B, et al.Propensity score-based comparison of long-term outcomes with 3-dimensional conformal radiotherapy vs intensity-modulated radiotherapy for esophageal cancer[J]. Int J Radiat Oncol Biol Phys, 2012,84(5):1078-1085. DOI: 10.1016/j.ijrobp.2012.02.015. [8] He L, Chapple A, Liao Z, et al.Bayesian regression analyses of radiation modality effects on pericardial and pleural effusion and survival in esophageal cancer[J]. Radiother Oncol, 2016,121(1):70-74. DOI: 10.1016/j.radonc.2016.08.005. [9] Bai XH, Dang J, Chen ZQ, et al.Comparison between intensity-modulated radiotherapy and three-dimensional conformal radiotherapy for their effectiveness in esophageal cancer treatment: a retrospective single institution study[J]. J Oncol, 2020:6582341. DOI: 10.1155/2020/6582341. [10] Lin CY, Huang WY, Jen YM, et al.Dosimetric and efficiency comparison of high-dose radiotherapy for esophageal cancer: volumetric modulated arc therapy versus fixed-field intensity-modulated radiotherapy[J]. Dis Esophagus, 2014,27(6):585-590. DOI: 10.1111/dote.12144. [11] Wang L, Li C, Meng X, et al.Dosimetric and radiobiological comparison of external beam radiotherapy using simultaneous integrated boost technique for esophageal cancer in different location[J]. Front Oncol, 2019,9:674. DOI: 10.3389/fonc.2019.00674. [12] Lin SH, Hobbs BP, Verma V, et al.Randomized phase IIB trial of proton beam therapy versus intensity-modulated radiation therapy for locally advanced esophageal cancer[J]. J Clin Oncol, 2020,38(14):1569-1579. DOI: 10.1200/JCO.19.02503. [13] Minsky BD, Pajak TF, Ginsberg RJ, et al.INT 0123 (radiation therapy oncology group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy[J]. J Clin Oncol, 2002,20(5):1167-1174. DOI: 10.1200/JCO.2002. 20.5.1167. [14] Welsh J, Settle SH, Amini A, et al.Failure patterns in patients with esophageal cancer treated with definitive chemoradiation[J]. Cancer, 2012,118(10):2632-2640. DOI: 10.1002/cncr.26586. [15] Chang CL, Tsai HC, Lin WC, et al.Dose escalation intensity-modulated radiotherapy-based concurrent chemoradiotherapy is effective for advanced-stage thoracic esophageal squamous cell carcinoma[J]. Radiother Oncol, 2017,125(1):73-79. DOI: 10.1016/j.radonc.2017.08.025. [16] Ren X, Wang L, Han C, et al.Retrospective analysis of safety profile of high-dose concurrent chemoradiotherapy for patients with oesophageal squamous cell carcinoma[J]. Radiother Oncol, 2018,129(2):293-299. DOI: 10.1016/j.radonc.2018.09.006. [17] 赵晶晶, 章文成, 张华雷, 等. 多中心食管鳞状细胞癌提高三维放疗剂量临床疗效分析——3JECROG R-03[J]. 中华放射肿瘤学杂志,2020,29(11):941-947. DOI: 10.3760/cma.j.cn113030-20191014-00417. Zhao JJ, Zhang WC, Zhang HL, et al.Clinical efficacy of dose escalation in 3-dimensional radiotherapy for patients with esophageal squamous cell carcinoma-multicenter retrospective analysis (3JECROG R-03)[J]. Chin J Radiat Oncol,2020,29(11):941-947. DOI: 10.3760/cma.j.cn113030-20191014-00417. [18] Sun X, Wang L, Wang Y, et al.High vs. low radiation dose of concurrent chemoradiotherapy for esophageal carcinoma with modern radiotherapy techniques: a meta-analysis[J]. Front Oncol, 2020,10:1222. DOI: 10.3389/fonc.2020.01222. [19] Song T, Liang X, Fang M, et al.High-dose versus conventional-dose irradiation in cisplatin-based definitive concurrent chemoradiotherapy for esophageal cancer: a systematic review and pooled analysis[J]. Expert Rev Anticancer Ther, 2015,15(10):1157-1169. DOI: 10.1586/14737140.2015.1074041. [20] Welsh JW, Seyedin SN, Allen PK, et al.Local control and toxicity of a simultaneous integrated boost for dose escalation in locally advanced esophageal cancer: interim results from a prospective phase I/II trial[J]. J Thorac Oncol, 2017,12(2):375-382. DOI: 10.1016/j.jtho.2016.10.013. [21] Chen D, Menon H, Verma V, et al.Results of a phase 1/2 trial of chemoradiotherapy with simultaneous integrated boost of radiotherapy dose in unresectable locally advanced esophageal cancer[J]. JAMA Oncol, 2019,5(11):1597-1604. DOI: 10.1001/jamaoncol.2019.2809. [22] Li C, Ni W, Wang X, et al.A phase I/II radiation dose escalation trial using simultaneous integrated boost technique with elective nodal irradiation and concurrent chemotherapy for unresectable esophageal cancer[J]. Radiat Oncol, 2019,14(1):48. DOI: 10.1186/s13014-019-1249-5. [23] Zhang Y, Feng W, Gao LT, et al.Long-term follow-up of a phase I/II trial of radiation dose escalation by simultaneous integrated boost for locally advanced esophageal squamous cell carcinoma[J]. Radiother Oncol, 2021,159:190-196. DOI: 10.1016/j.radonc.2021.03.031. [24] 徐裕金, 朱卫国, Liao Zhongxing, 等. 同步放化疗60 Gy对比50 Gy剂量治疗不可手术食管鳞状细胞癌的多中心随机对照研究[J]. 中华医学杂志,2020,100(23):1783-1788. DOI:10.3760/cma.j.cn112137-20200303-00574. Xu YJ, Zhu WG, Liao ZX, et al.A multicenter randomized prospective study of concurrent chemoradiation with 60 Gy versus 50 Gy for inoperable esophageal squamous cell carcinoma[J]. Natl Med J China,2020,100(23):1783-1788. DOI:10.3760/cma.j.cn112137-20200303-00574. [25] Hulshof MCCM, Geijsen D, Rozema T, et al.A randomized controlled phase III multicenter study on dose escalation in definitive chemoradiation for patients with locally advanced esophageal cancer: ARTDECO study[J]. J Clin Oncol, 2020, 38(4_suppl): 281-281. DOI:10.1200/jco.2020.38.4_suppl.281. [26] Brower JV, Chen S, Bassetti MF, et al.Radiation dose escalation in esophageal cancer revisited: a contemporary analysis of the national cancer data base, 2004 to 2012[J]. Int J Radiat Oncol Biol Phys, 2016,96(5):985-993. DOI: 10.1016/j.ijrobp.2016.08.016. [27] 欧广飞, 汪楣, 王绿化, 等. 食管癌术前放疗后病理反应与预后的关系[J].中华肿瘤杂志,2003,25(3):278-281. DOI: 10.3760/j.issn:0253-3766.2003.03.021. Ou GF, Wang M, Wang LH, et al.Relation between pathologic tumor response to preoperative radiotherapy and the prognosis in patients with esophageal carcinoma[J].Chin J Oncol,2003,25(3):278-281. DOI: 10.3760/j.issn:0253-3766.2003.03.021. [28] Rice TW, Lerut TE, Orringer MB, et al.Worldwide esophageal cancer collaboration: neoadjuvant pathologic staging data[J]. Dis Esophagus, 2016,29(7):715-723. DOI: 10.1111/dote.12513. [29] Liu SL, Xi M, Yang H, et al.Is there a correlation between clinical complete response and pathological complete response after neoadjuvant chemoradiotherapy for esophageal squamous cell cancer?[J]. Ann Surg Oncol, 2016,23(1):273-281. DOI: 10.1245/s10434-015-4764-0. [30] Yang H, Liu H, Chen Y, et al.Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): a phase III multicenter, randomized, open-label clinical trial[J]. J Clin Oncol, 2018,36(27):2796-2803. DOI: 10.1200/JCO.2018.79.1483. [31] Du D, Song T, Liang X, et al.Concurrent chemoradiotherapy with elective lymph node irradiation for esophageal cancer: a systemic review and pooled analysis of the literature[J]. Dis Esophagus, 2017,30(2):1-9. DOI: 10.1111/dote.12471. [32] 祝淑钗, 李巧芳, 张雪原,等. 食管癌根治性调强放疗靶区范围对患者预后的影响[J]. 中华肿瘤杂志, 2020, 42(12): 1040-1047. DOI:10.3760/cma.j.cn112152-2019 1225- 00842. Zhu SC, Li QF, Zhang XY, et al.Clinical outcomes of different irradiation ranges in definitive intensity-modulated radiotherapy for esophageal cancer[J]. Chin J Oncol, 2020, 42(12): 1040-1047. DOI:10.3760/cma.j.cn112152-2019 1225-00842. [33] Wang X, Miao C, Chen Z, et al.Can involved-field irradiation replace elective nodal irradiation in chemoradiotherapy for esophageal cancer? A systematic review and meta-analysis[J]. Onco Targets Ther, 2017,10:2087-2095. DOI: 10.2147/OTT.S130285. [34] Li M, Zhang X, Liao Z, et al.Failure patterns after definitive chemoradiation therapy with involved-field irradiation for locally advanced esophageal squamous cell carcinoma[J]. Int J Radiat Oncol Biol Phys, 2014, 90: S12. DOI:10.1016/j.ijrobp.2014.05.092. [35] Yamashita H, Abe O, Nakagawa K.Involved-field irradiation concurrently combined with nedaplatin/5-fluorouracil for inoperable esophageal cancer on basis of 18FDG-PET scans: a long follow-up results of phase II study[J]. Radiother Oncol, 2017,123(3):488. DOI: 10.1016/j.radonc.2017.04.002. [36] Lyu J, Yisikandaer A, Li T, et al.Comparison between the effects of elective nodal irradiation and involved-field irradiation on long-term survival in thoracic esophageal squamous cell carcinoma patients: a prospective, multicenter, randomized, controlled study in China[J]. Cancer Med, 2020,9(20):7460-7468. DOI: 10.1002/cam4.3409. [37] Liu M, Zhao K, Chen Y, et al.Evaluation of the value of ENI in radiotherapy for cervical and upper thoracic esophageal cancer: a retrospective analysis[J]. Radiat Oncol, 2014,9:232. DOI: 10.1186/s13014-014-0232-4. [38] Polk A, Vaage-Nilsen M, Vistisen K, et al.Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors[J]. Cancer Treat Rev, 2013,39(8):974-984. DOI: 10.1016/j.ctrv.2013.03.005. [39] Conroy T, Galais MP, Raoul JL, et al.Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial[J]. Lancet Oncol, 2014,15(3):305-314. DOI: 10.1016/S1470-2045(14)70028-2. [40] Chen Y, Ye J, Zhu Z, et al.Comparing paclitaxel plus fluorouracil versus cisplatin plus fluorouracil in chemoradiotherapy for locally advanced esophageal squamous cell cancer: a randomized, multicenter, phase III clinical trial[J]. J Clin Oncol, 2019,37(20):1695-1703. DOI: 10.1200/JCO.18.02122. [41] Ai D, Ye J, Chen Y, et al.Final results of a phase III randomized trial of comparison of three paclitaxel-based regimens concurrent with radiotherapy for patients with local advanced esophageal squamous cell carcinoma (ESO-Shanghai2)[J]. Int J Radiat Oncol Biol Phys, 2020, 108(3, Supplement): S45. DOI: 10.1016/j.ijrobp.2020. 07.2158. [42] Song GM, Tian X, Liu XL, et al.Concurrent chemo-radiotherapy with S-1 as an alternative therapy for elderly Chinese patients with non-metastatic esophageal squamous cancer: evidence based on a systematic review and meta-analysis[J]. Oncotarget, 2017,8(23):37963-37973. DOI: 10.18632/oncotarget.16302. [43] Lv S, Fang M, Yang J, et al.Long-term results of definitive concurrent chemoradiotherapy using S-1 in the treatment of geriatric patients with esophageal cancer[J]. Onco Targets Ther, 2016,9:5389-5397. DOI: 10.2147/OTT.S107668. [44] Ji Y, Du X, Tian Y, et al.A phase II study of S-1 with concurrent radiotherapy in elderly patients with esophageal cancer[J]. Oncotarget, 2017,8(47):83022-83029. DOI: 10.18632/oncotarget.20938. [45] Kato K, Sun JM, Shah MA, et al.Pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase 3 KEYNOTE-590 study[J]. Annals of Oncology, 2020, 31: S1192-S1193. DOI: 10.1016/j.annonc.2020.08.2298. [46] Pang Q, Zhang W, Zhao J, et al.Safety and efficacy of PD-1 antibody SHR-1210 combined with concurrent chemoradiotherapy to treat locally advanced esophageal squamous cell carcinoma: a phase Ib clinical trial[J]. Int J Radiat Oncol Biol Phys, 2020, 108(3): S46. DOI: 10.1016/j.ijrobp.2020.07.2160. [47] Kelly RJ, Ajani JA, Kuzdzal J, et al.Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer[J]. N Engl J Med, 2021,384(13):1191-1203. DOI: 10.1056/NEJMoa2032125.